AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27932068
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine 0.2 mg/kg every 3 weeks
Trial: 27932068
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine 0.4 mg/kg every 3 weeks
Trial: 27932068
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine 0.3 mg/kg every 6 weeks
Trial: 27932068
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine 0.4 mg/kg every 6 weeks
Trial: 27932068
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine 0.8 mg/kg every 3 weeks
Trial: 27932068
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (various doses)
Trial: 27932629
Drug: London Chest
RxNorm normalized name: London planetree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: London Chest Activities of Daily Living Scale
Trial: 27933199
Drug: RCI 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCI 40 U daily
Trial: 27933199
Drug: RCI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCI treatment
Trial: 27933679
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation for 2 weeks
Trial: 27935524
Drug: Low urinary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low urinary potassium excretion (UKV <55 mmol/24 h for women; <65 mmol/24 h for men)
Trial: 27935524
Drug: Mean urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean urinary potassium excretion (UKV) in RTRs
Trial: 27935737
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) for 30 minutes, three times weekly for 4 weeks
Trial: 27935867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OTX015 and everolimus
Trial: 27935867
Drug: OTX015 as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX015 as single agent
Trial: 27935867
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with everolimus
Trial: 27938896
Drug: Home administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home administration of intranasal LAIV by parents
Trial: 27938911
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 mg/kg) infusion for 10 minutes
Trial: 27942917
Drug: LJM716 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJM716 (40 mg/kg, intravenously, once weekly in 28-day cycles)
Trial: 27943107
Drug: IDegLira once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IDegLira once daily
Trial: 27943107
Drug: Unchanged GLP-1RA
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Unchanged GLP-1RA therapy
Trial: 27955684
Drug: Pertuzumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (840 mg loading, 420 mg maintenance doses) and Trastuzumab (8 mg/kg loading, 6 mg/kg maintenance doses), followed by Vinorelbine (25 mg/m2)
Trial: 27956157
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg once daily until progression or unacceptable toxicity
Trial: 27956421
Drug: Miltefosine (Impavido)
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine (Impavido) at a nominal dose of 2.5 mg/kg/day for 28 days
Trial: 27959731
Drug: Decitabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (20 mg/m²/day for 10 consecutive days in monthly cycles)
Trial: 27964869
Drug: Voluntary methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary methadone treatment in VTCs
Trial: 27964869
Drug: Compulsory drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compulsory drug detention centres (CDDCs)
Trial: 27965789
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% ropivacaine
Trial: 27965789
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml 0.33% ropivacaine
Trial: 27965789
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml 0.25% ropivacaine
Trial: 27965798
Drug: Probiotics administered
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics administered to mechanically ventilated critically ill patients
Trial: 27965808
Drug: Multi-component physiotherapist-led
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component physiotherapist-led intervention including a 40-min education module, guided goal-setting, action planning, wristband activity tracker, and weekly follow-up phone calls.
Trial: 27965809
Drug: Glycerin suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin suppository (250 mg)
Trial: 27965809
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg glycerin suppository placed in the diaper)
Trial: 27965816
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection on clinical history, diagnostic path, treatment, and urine culture
Trial: 27965841
Drug: Behavioral activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral activation (BA) group therapy
Trial: 27965866
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone (Prometrium, 200 mg) vaginally every night from gestational week 16 to 36
Trial: 27965885
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (two 30-45 min sessions per week for three consecutive weeks, in addition to care as usual)
Trial: 27966809
Drug: Carboxypeptidase G2
RxNorm normalized name: Carboxypeptidase G2
DrugBank: Glucarpidase (DB08898)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Carboxypeptidase G2 (CPDG) administered to 47 children
Trial: 27966809
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (5 g/m2)
Trial: 27967215
Drug: Intramuscular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular triamcinolone acetonide (TA)
Trial: 27977390
Drug: Population pharmacokinetics
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population pharmacokinetics models
Trial: 27978569
Drug: Low-vision devices
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-vision devices with therapy
Trial: 27978569
Drug: Low-vision devices
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-vision devices without therapy
Trial: 27979025
Drug: Atopy patch
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopy patch tests (APTs) with locally lyophilized food allergens
Trial: 27979025
Drug: Atopy patch
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopy patch tests (APTs) for D. farinae, D. pteronyssinus, and American cockroach
Trial: 27980771
Drug: Neurobiologically based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurobiologically based five-day treatment for anorexia nervosa
Trial: 27980787
Drug: Group training
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group training program based on cognitive-behavioral principles and skills from Dialectical Behavior Therapy (DBT)
Trial: 27980877
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of 4-mg triamcinolone acetonide (TA) in 100 μL
Trial: 27986651
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg, 5 doses, 2 weeks apart)
Trial: 27988497
Drug: Moderately reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately reduced kidney function (eGFR 30 to 60 mL/min per 1.73 m²)
Trial: 27988497
Drug: Normal kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal kidney function (eGFR >60 mL/min per 1.73 m²)
Trial: 27989789
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (programmed with 1 or 2 therapy zones)
Trial: 27989886
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of rosuvastatin daily for 8 to 12 weeks
Trial: 27992451
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg BID with Vinorelbine 30 mg/m2 IV days 1,8 every 21 days
Trial: 27993904
Drug: CPET after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPET after treatment of iliofemoral occlusive arterial disease
Trial: 27993904
Drug: CPET before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPET before treatment of iliofemoral occlusive arterial disease
Trial: 27993926
Drug: HOMA-IR (HOMA-insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA-IR (HOMA-insulin resistance)
Trial: 27996967
Drug: AdhAQP1 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AdhAQP1 administration
Trial: 27998970
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 on day 1, Cisplatin 50 mg/m2 on day 2, Veliparib escalating doses from 50 to 400 mg orally two times daily on days 1-7
Trial: 27999035
Drug: Intravenous intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous intermittent dosing (ID) of vancomycin
Trial: 27999035
Drug: Continuous dosing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dosing (CD) of vancomycin
Trial: 27999035
Drug: Vancomycin therapy
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin therapy (general)
Trial: 27999038
Drug: ABX464 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 (50, 100, 150 or 200 mg)
Trial: 27999040
Drug: Cefazolin administered
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administered before surgical incision, before cessation of CPB, and after surgery.
Trial: 27999040
Drug: Cefazolin dosing
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin dosing regimen with an additional bolus dose at the start of CPB.
Trial: 27999040
Drug: Cefazolin dosing
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin dosing regimen during prolonged surgery with preserved renal function.
Trial: 27999607
Drug: Loquat Leaf
RxNorm normalized name: Belladonna Leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loquat Leaf Extract (500 mg, 50.94 mg of Ursolic Acid)
Trial: 27999670
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy group treatment
Trial: 28000190
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) combined with soluble dietary fiber (pectin, 8 g/d) and probiotics (bifid triple viable capsules, twice per day) for 4 weeks after initial treatment with vancomycin 500 mg orally twice per day for 3 days.
Trial: 28003133
Drug: Placebo pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pulsed shortwave therapy (control group), 30 minutes per session.
Trial: 28003301
Drug: Sublingual video-microscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual video-microscopy
Trial: 28005959
Drug: P-TIV (Proteosome-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 1 x 30 μg, 2 x 30 μg, 2 x 15 μg
Trial: 28005959
Drug: P-TIV (Proteosome-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine)
Trial: 28005959
Drug: P-TIV (Proteosome-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-TIV (Proteosome-adjuvanted trivalent inactivated influenza vaccine) - 2 doses vs 1 dose
Trial: 28007027
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with vancomycin-loaded calcium sulfate and vancomycin-loaded PMMA
Trial: 28007027
Drug: Antibiotic-loaded PMMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-loaded PMMA (Control Group)
Trial: 28007741
Drug: Intravascular ultrasound-guided
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular ultrasound-guided drug-eluting stents implantation with ASM
Trial: 28007741
Drug: Intravascular ultrasound-guided
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular ultrasound-guided drug-eluting stents implantation without ASM
Trial: 28011051
Drug: Neoadjuvant temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant temozolomide (TMZ) at a daily dose of 75 mg/m²
Trial: 28011608
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for Mycobacterium abscessus lung disease
Trial: 28012848
Drug: Fluorescently labeled
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescently labeled peptide (76.4 μmol/L) administered topically to proximal colon
Trial: 28012848
Drug: Fluorescently labeled
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescently labeled peptide (2.25 μmol/L and 76.4 μmol/L) administered topically to proximal colon
Trial: 28013265
Drug: High drug
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Trial: 28013265
Drug: Low drug
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low drug exposure to Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Trial: 28013405
Drug: D2C7-(scdsFv)-PE38KDEL (D2C7-IT)
RxNorm normalized name: D2C7 immunotoxin
DrugBank: D2C7 immunotoxin (DB17540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) administered via intratumoral convection-enhanced delivery for 72 hours.
Trial: 28017350
Drug: hs-cTnT ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT ≥ 14 ng/l
Trial: 28017350
Drug: hs-cTnT <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT < 14 ng/l, overweight
Trial: 28017350
Drug: hs-cTnT <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT < 14 ng/l, obese
Trial: 28017350
Drug: hs-cTnT ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT ≥ 14 ng/l, overweight
Trial: 28017350
Drug: hs-cTnT ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT ≥ 14 ng/l, obese
Trial: 28017967
Drug: Duvelisib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duvelisib and Venetoclax combination
Trial: 28018669
Drug: Omeprazole-clopidogrel combination
RxNorm normalized name: omeprazole, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole-clopidogrel combination
Trial: 28018669
Drug: Pantoprazole-clopidogrel combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole-clopidogrel combination
Trial: 28025928
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care using the Dader Method
Trial: 28029055
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hsTnT, NT-proBNP, and hsCRP with the GRACE score
Trial: 28029383
Drug: M-BET (multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-BET (multicomponent behavioral treatment and exercise therapy)
Trial: 28029383
Drug: α-blocker (tamsulosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-blocker (tamsulosin, 0.4-mg tablet nightly)
Trial: 28029383
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (M-BET + α-blocker)
Trial: 28029529
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) plus sofosbuvir (400 mg) fixed-dose combination tablet once daily for 6 weeks
Trial: 28029918
Drug: Selumetinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (20 to 30 mg/m², administered twice daily on a continuous dosing schedule in 28-day cycles)
Trial: 28029927
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor (CAR)-engineered T cells targeting IL13Rα2, administered multiple times over 220 days through intracranial delivery routes.
Trial: 28030578
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of non-right axis deviation, NT-proBNP<333pg/ml, SO2≥95.5%, and WHO functional class I-II
Trial: 28030579
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg and Deleobuvir 600 mg (Child-Pugh A) or 400 mg (Child-Pugh B) twice-daily with weight-based ribavirin for 24 weeks
Trial: 28031441
Drug: M5.15 activity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M5.15 activity in patients responding to treatment
Trial: 29065923
Drug: Intragastric balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric balloon (IGB) treatment for 6 months
Trial: 28031816
Drug: Ipilimumab at
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab at 3 mg/kg with peginterferon alfa-2b at 2 μg/kg/week
Trial: 28032129
Drug: Oral crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral crizotinib at dose levels of 100, 130, 165, 215, 280 and 365 mg/m
Trial: 28032216
Drug: Aprepitant 125/80/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedule and oral ondansetron 8 mg po q12 h
Trial: 28034990
Drug: Alisertib administered
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib administered for 7 days after conventional induction with cytarabine and idarubicin
Trial: 28034993
Drug: Lenalidomide combined
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide combined with intensive chemotherapy (daunorubicin 45 mg/m2)
Trial: 28034993
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (daunorubicin 45 mg/m2)
Trial: 28039079
Drug: Post-transplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant cyclophosphamide 50 mg/kg (days +3 and +4) and tacrolimus/mycophenolate mofetil (T/MMF) (day +5 forward)
Trial: 28039079
Drug: Post-transplant cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant cyclophosphamide + T/MMF combination
Trial: 28039155
Drug: Cabazitaxel plus
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel plus abiraterone plus prednisone (5 mg twice daily)
Trial: 28039250
Drug: L-view scoring
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-view scoring system
Trial: 28039250
Drug: Paired T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paired T and L-view scores